PB0091 - ADAMTS13 in the diagnosis of the severity of COVID-19 mortality

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

LS

Luděk Slavík, PhD

Head of laboratory
Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc; University Hospital Olomouc
Olomouc, Olomoucky kraj, Czech Republic

Co-Author(s)

JU

Jana Ulehlova

laboratory specialist
Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc; University Hospital Olomouc
Olomouc, Olomoucky kraj, Czech Republic
PB

Pavla Bradacova

laboratory specialist
Department of Clinical Hematology, Masaryk Hospital Ústí nad Labem
Usti nad Labem, Ustecky kraj, Czech Republic
MJ

Michaela Jancova

laboratory specialist
Hematology-Transfusion Department, Institut for Clinical and Experimental Medicine
Praha, Hlavni mesto Praha, Czech Republic
JP

Jana Prochazkova

hematology specialist
Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc; University Hospital Olomouc
Olomouc, Olomoucky kraj, Czech Republic
AH

Antonin Hlusi

hematology specialist
Department of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc; University Hospital Olomouc
Olomouc, Olomoucky kraj, Czech Republic

Background: Patients with severe respiratory failure come to the hospital emergency room, where they are triaged to support lung ventilation. Coagulation markers are one of the important methods for triage. The main method used so far is DDIM. Their elevation is due to the activation of coagulation with prothrombogenic potential, which manifests itself mainly in the microcirculation.
These processes lead to the excessive release of Von Willebrand factor (VWF) from the Weibel Palade bodies and its cleavage by ADAMTS13, which is thus consumed.

Aims: The aim of our study was to assess the effect of ADAMTS13 levels on the prognosis of patients with acute respiratory failure due to COVID-19 infection.

Methods: 46 patients coming to the emergency department were examined and admitted to the intensive care unit to support lung function based on clinical symptoms and elevated D-Dimers.
These patients were retrospectively examined for ADAMTS13.

Results: The levels of ADAMTS13 showed a statistically significant difference (P=0,02) that corresponded to the clinical course of severe respiratory failure due to COVID-19 infection. Ninghteen patients with a relatively mild course had an ADAMTS13 level of 0,74 IU/ml (0,28 -1,14 IU/ml), in contrast to a skip of 27 patients with a severe course, which had an ADAMTS13 level of 0,54 IU/ml (0.25 – 1,01 IU/ml).

Conclusion(s): The levels of D-Dimer as a commonly used marker in triage of the COVID-19 severity infection is mainly due to the activation of coagulation and its manifestations, especially in the microcirculation. The level of ADAMTS13 is a key marker in the early prognosis of the severity of COVID-19 due to pulmonary insufficiency, whereas D-DIm is only a consequence of this process.

Supported by grant LF-2022-001 and MH CZ - DRO (FNOl, 00098892)